Evidence map›Paper›PMID 30949162›Full record

ReviewFrontiers in immunology2019

Comprehensive Review of Human

Janna Heide, Kerrie C Vaughan, Alessandro Sette, Thomas Jacobs, Julian Schulze Zur Wiesch

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. IntelligentFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Clinical development of therapeutic mRNA applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Article
  7. Article
  8. Computational vaccine development against protozoa.Computational and structural biotechnology journal · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Computational Clues of Immunogenic Hotspots inBioMed research international · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janna HeideInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kerrie C VaughanDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Thomas JacobsProtozoa Immunology, Bernhard-Nocht-Institute of Tropical Medicine, Hamburg, Germany.
Julian Schulze Zur WieschInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

NIAID NIH HHS HHSN272201200010C
6 · The paper itself

Abstract

Control of malaria is an important global health issue and there is still an urgent need for the development of an effective prophylactic vaccine. Multiple studies have provided strong evidence that

Indexed as

Antigens, ProtozoanCD8-Positive T-LymphocytesEpitopes, T-LymphocyteHumansMalaria, FalciparumMalaria VaccinesPlasmodium falciparumAntigens, ProtozoanEpitopes, T-LymphocyteMalaria VaccinesCD8+cytotoxic T cellsHLAmalariaPlasmodium falciparumrestrictionT cell epitope

Identifiers

PMID30949162
PMCPMC6438266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.